Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers.

SARS-CoV-2 anti-spike antibody cVNT eCLIA neutralizing antibodies sVNT

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
02 02 2023
Historique:
received: 13 10 2022
revised: 03 01 2023
accepted: 28 01 2023
entrez: 28 2 2023
pubmed: 1 3 2023
medline: 3 3 2023
Statut: epublish

Résumé

Vaccination against COVID-19 is the main public health approach to fight against the pandemic. The Spike (S) glycoprotein of SARS-CoV-2 is the principal target of the neutralizing humoral response. We evaluated the analytical and clinical performances of a surrogate virus neutralization test (sVNT) compared to conventional neutralization tests (cVNTs) and anti-S eCLIA assays in recovered and/or vaccinated healthcare workers. Our results indicate that sVNTs displayed high specificity and no cross-reactivity. Both eCLIA and sVNT immunoassays were good at identifying cVNT serum dilutions ≥1:16. The optimal thresholds when identifying cVNT titers ≥1:16, were 74.5 U/mL and 49.4 IU/mL for anti-S eCLIA and sVNT, respectively. Our data show that neutralizing antibody titers (Nab) differ from one individual to another and may diminish over time. Specific assays such as sVNTs could offer a reliable complementary tool to routine anti-S serological assays.

Identifiants

pubmed: 36851641
pii: v15020426
doi: 10.3390/v15020426
pmc: PMC9958856
pii:
doi:

Substances chimiques

Antibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
N Engl J Med. 2007 Sep 13;357(11):1162-3
pubmed: 17855683
Lancet. 2020 Jul 25;396(10246):e6-e7
pubmed: 32653078
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Emerg Microbes Infect. 2020 Dec;9(1):900-902
pubmed: 32380903
J Infect. 2020 Sep;81(3):420-426
pubmed: 32504745
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32398307
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33303562
Vaccine. 2020 Feb 24;38(9):2250-2257
pubmed: 31767462
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139419
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Commun. 2020 Oct 8;11(1):5064
pubmed: 33033249
J Med Virol. 2005 Oct;77(2):147-50
pubmed: 16121363
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822
pubmed: 32249185
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Emerg Microbes Infect. 2021 Dec;10(1):152-160
pubmed: 33407005
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Nat Commun. 2020 Sep 17;11(1):4698
pubmed: 32943630
J Infect Dis. 2018 May 5;217(11):1728-1739
pubmed: 29741740
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539
pubmed: 32745196
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Clin Microbiol Infect. 2020 Sep;26(9):1178-1182
pubmed: 32593741
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 32917729
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
Adv Virus Res. 2016;96:245-286
pubmed: 27712626
JAMA. 2020 Nov 3;324(17):1781-1782
pubmed: 32940635
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2020 Jun;20(6):352
pubmed: 32346091
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Cell Host Microbe. 2020 Mar 11;27(3):325-328
pubmed: 32035028
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Transfus Med. 2021 Jun;31(3):167-175
pubmed: 33333627
Emerg Microbes Infect. 2020 Dec;9(1):2394-2403
pubmed: 33043818
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Clin Chem Lab Med. 2020 Jun 25;58(7):1037-1052
pubmed: 32459192

Auteurs

Lina Mouna (L)

Virology Department, Hôpital Paul Brousse, INSERM U1193, AP-HP, Université Paris Saclay, 94804 Villejuif, France.

Mehdi Razazian (M)

Virology Department, Hôpital Paul Brousse, INSERM U1193, AP-HP, Université Paris Saclay, 94804 Villejuif, France.
Institute for Physiology and Pathophysiology, Johannes Kepler University Linz, 4040 Linz, Austria.

Sandra Duquesne (S)

Virology Department, Hôpital Paul Brousse, INSERM U1193, AP-HP, Université Paris Saclay, 94804 Villejuif, France.

Anne-Marie Roque-Afonso (AM)

Virology Department, Hôpital Paul Brousse, INSERM U1193, AP-HP, Université Paris Saclay, 94804 Villejuif, France.

Christelle Vauloup-Fellous (C)

Virology Department, Hôpital Paul Brousse, INSERM U1193, AP-HP, Université Paris Saclay, 94804 Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH